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Abstract. Xmn1 polymorphism is a known factor, which increases fetal haemoglobin production. 
Among the inherited disorders of blood, thalassaemia and Sickle Cell Diseases contributes to a 
major bulk of genetic diseases in India. Our aim was to verify 
as a modulating factor in sickle cell patients and frequency of the polymorphism in Indian sickle 
cell patients.  60 sickle homozygous and 75 sickle beta thalassemia patients were included and 5 ml 
blood  sample  was  collected  from  them.  Screening  of  sickle  patients  was  done  by  HPLC.  An 
automated cell analyzer SYSMEX (K
of patients. Xmn1 polymorphism analysis was done by PCR
applied to analysis of variance between groups. Among the sickle patients 27 were heterozygous (+/
) and 19 were homozygous (+/+) while 30 were heterozygous (+/
sickle β-thalassemia patients. Extremely significant differences (p
parameters seen among patients with Xmn1 carrier and without the X
clinical  symptoms  were  barely  visible  and  higher  HbF  level  with  X
Presence  of  Xmn1  polymorphism  in  sickle  cell
distinguished  in  the  sickle  cell  patients.  We  conclude  that  the  phenotypes  of  Indian  sickle  cell 
patients were greatly influenced by X
Introduction. The C-T substitution at position 
the  Gy  globin  gene,  referred  to  as  the  Xmn1
polymorphism, is a common sequence variant in all 
population  groups, present at  a frequency of 0.32 to 
0.35.
1 Clinical  studies  have  shown  that  under 
conditions  of  hematopoietic  stress,  for  example  in 
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polymorphism is a known factor, which increases fetal haemoglobin production. 
Among the inherited disorders of blood, thalassaemia and Sickle Cell Diseases contributes to a 
major bulk of genetic diseases in India. Our aim was to verify the role of the X
as a modulating factor in sickle cell patients and frequency of the polymorphism in Indian sickle 
cell patients.  60 sickle homozygous and 75 sickle beta thalassemia patients were included and 5 ml 
ed  from  them.  Screening  of  sickle  patients  was  done  by  HPLC.  An 
automated cell analyzer SYSMEX (K-4500 Model) was used to analyze the Complete Blood Count 
1 polymorphism analysis was done by PCR-RFLP and one
nalysis of variance between groups. Among the sickle patients 27 were heterozygous (+/
) and 19 were homozygous (+/+) while 30 were heterozygous (+/-) and 24 were homozygous (+/+) in 
thalassemia patients. Extremely significant differences (p-value <0.001) of hematological 
parameters seen among patients with Xmn1 carrier and without the Xmn1 carrier. In our cases the 
clinical  symptoms  were  barely  visible  and  higher  HbF  level  with  Xmn1  carriers  were  found. 
1  polymorphism  in  sickle  cell patients  with  higher  HbF  were  phenotypically 
distinguished  in  the  sickle  cell  patients.  We  conclude  that  the  phenotypes  of  Indian  sickle  cell 
patients were greatly influenced by Xmn1polymorphism.
T substitution at position –158 of 
globin  gene,  referred  to  as  the  Xmn1-
polymorphism, is a common sequence variant in all 
population  groups, present at  a frequency of 0.32 to 
Clinical  studies  have  shown  that  under 
conditions  of  hematopoietic  stress,  for  example  in 
homozygous -thalassemia and sickle cell disease, the 
presence of the Xmn1- G
response. This could explain why the same mutations 
on  different   chromosomal  backgrounds  are 
associated with disease of different clinical severity.
Increased levels of fetal hemoglobin (Hb F or 
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polymorphism is a known factor, which increases fetal haemoglobin production. 
Among the inherited disorders of blood, thalassaemia and Sickle Cell Diseases contributes to a 
the role of the Xmn1 polymorphism 
as a modulating factor in sickle cell patients and frequency of the polymorphism in Indian sickle 
cell patients.  60 sickle homozygous and 75 sickle beta thalassemia patients were included and 5 ml 
ed  from  them.  Screening  of  sickle  patients  was  done  by  HPLC.  An 
4500 Model) was used to analyze the Complete Blood Count 
RFLP and one-way ANOVA  test was 
nalysis of variance between groups. Among the sickle patients 27 were heterozygous (+/-
) and 24 were homozygous (+/+) in 
<0.001) of hematological 
1 carrier. In our cases the 
1  carriers  were  found. 
patients  with  higher  HbF  were  phenotypically 
distinguished  in  the  sickle  cell  patients.  We  conclude  that  the  phenotypes  of  Indian  sickle  cell 
thalassemia and sickle cell disease, the 
site favors a higher Hb F 
response. This could explain why the same mutations 
chromosomal  backgrounds  are 
associated with disease of different clinical severity.
2,3 
Increased levels of fetal hemoglobin (Hb F or a2 γ2) Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
are  of  no  consequence  in  healthy  adults,  but  confer 
major  clinical  benefits  in  patients  with  sickle  cell 
anemia  (SCA)  and  β- thalassemia,  diseases  that 
represent  major  public  health  problems.
4  Fetal 
hemoglobin (Hb F or a2 γ2) is predominant in red cells 
of  the  fetus  and  the  newborn  baby,  and  is  largely 
replaced after birth by adult hemoglobin (α2β2). The 
two types of γ chains of Hb F (Gγ and Aγ) differ at 
position 136 (glycine versus alanine) and are produced 
by closely-linked genes of the β -globin gene cluster. In 
normal adults, red cells have less than 1% Hb F, and 
Gγ accounts for some 40% of total γ chain.
5 Genetic 
variation of Gγ values has been observed in sickle cell 
anemia  (SS)  patients,  whose  increased  Hb  F  levels 
facilitate such studies. Although most have 40% Gγ, 
some have Gγ values of 60% to 70%.
6 About 5% of 
black  sickle  cell  patients  are  heterozygous  for  the 
normal -Gγ  -Aγ  and  a  mutant  -Gγ  -Aγ  chromosome 
with  both  genes producing Gγ  globin; they have Gγ 
values of about 70%.
7-9Approximately 1/6 black sickle 
cell and 2/3 black β -thalassemia heterozygotes have 
high Gγ values of about 60%. It has been estimated 
that in India with a population of 100 million at the 
millennium (2000) and a birth rate of 25/1000, there 
would  be  about  45  million  carriers  and  about  9000 
infants  born  each  year  with  haemoglobinopathies.
10  
Among  the  genetic  factors  known  to  affect  HbF 
production are DNA sequence variations within the β -
globin gene cluster. In particular, the (C-T) variation at
position – 158 upstream of the Gγ globin gene, which 
is  detectable  by  the  restriction  enzyme  Xmn1.  The 
sequence variation has been shown to increase Hb F 
levels  in  β-thalassaemia  anemia.
11,12,13    There  is  a 
paucity  of  data  for  the  effect  of  the  Xmn1 
polymorphism on the phenotype of Indian sickle cell 
patient; thus our aim was to evaluate the role of the 
Xmn1 polymorphism as a modulating factor in sickle 
cell patients and its frequency. 
Material  and Methods.  Subjects  were  60  sickles 
homozygous  and  75  sickle  beta  thalassemia  patients 
(29  patients  were  HbSβ
+ while  46  patients  were 
HbSβ
0).  About 5 ml blood sample was collected from 
hematology outpatient department AIIMS; after taking 
their  consent.  Study was  approved  from institutional 
ethical  committee.    Clinical  evaluation  was  done 
during  physical  examination  (visually  appeared)  as 
well  as  laboratory  evaluation.  Age  of  onset  of 
splenomegaly  and jaundice  was  <10 year and the 
presence of anemia was evaluated through hemogram 
analysis.  Complete  blood  count  and  red  cell  indices 
were measured by automated cell analyzer (SYSMEX 
K-4500,  Kobe  Japan).  Quantitative  assessment  of 
hemoglobin  Hb  F,  Hb  A,  Hb  A2  and  Hb  S  and 
diagnosis  of  HbSS  and  HbSβ-thalassemia  was 
performed by high performance liquid chromatography 
(HPLC-Bio-Rad-Variant
TM Bio Rad, CA, USA). DNA 
extraction  done  by  phenol  chloroform  method  and 
DNA  quantification  done  by  nano  drop 
spectrophotometer. Xmn1 polymorphism analysis was 
done by PCR-RFLP method as per Sutton
14et.al (1989). 
A one-way ANOVA  test was applied  to analysis of 
variance  between  groups.  P-value  <0.05  were 
considered statistical significant.  Presence of clinical 
symptoms with and without Xmn1polymorphism was 
used to for comparison of clinical features. 
Result.  Sixty  sickle  homozygous  (35  male  and  25 
female with mean age 11.32±7.61 years) and 75 sickle 
β-thalassemia  (57  male  and  18  female  with  mean 
age12±8.33 years) patients were characterized. Out of 
60  sickle  homozygous  patients;  27  (45%)  were   
heterozygous  (+/-)  and  19  (31.67%)  were   
homozygous (+/+) while 30(40%) were heterozygous 
and 24(32%) were homozygous in sickle β-thalassemia 
for Xmn1 polymorphism. Fourteen (23.33%) patient in 
sickle homozygous and 21(28%) patients in sickle β-
thalassemia were normal for Xmn1 polymorphism. The 
frequency  of  the  Xmn1  polymorphism  was  higher 
among  sickle  homozygous  than  sickle  β-thalassemia 
patients.  Clinical  severity  were  improved  with 
homozygous (+/+) Xmn1 polymorphism in sickle cell 
anemia  as  well  as  sickle  β-thalassemia  patients. 
Reticulocytes, haemoglobin and red cell indices were  
higher in  Xmn1carriers than non carriers  and found 
extremely  statistically  significant  (p-value  <0.001).  
The explanation to the improvement of RBCs in Xmn1 
carriers  is that the  anemia was less and overall red cell 
indices  and  Hb  value  was  improved. 
Hyperpigmentation  was  found  in  a  few  cases. 
Splenomegaly , gall stone, painful crisis, jaundice and 
frequency of blood transfusion  in relation with HbF 
and Xmn1 polymorphism were lesser in Xmn1 carriers 
in comparison to non-carriers and found  statistically 
significant (p-value <0.001). Details of haematological 
parameters and clinical parameters of HbSS and HbSβ-
thalassemia  are  given  in  table  1,  2,  3  and  4
respectively. 
Discussion.  Fetal  hemoglobin  (HbF)  genes  are 
genetically  regulated  and  the  level  of  HbF  and  its 
distribution  among  sickle  erythrocytes  is  highly 
variable. Hb F is the major genetic modulator of the 
hematological  and  clinical  features  of  sickle  cell 
disease with the  Senegal and Saudi-Indian  haplotype 
which gives its beneficial effects to the pateints.
15,  16 
Many  epidemiological  studies  suggested  that  disease 
complications  most  closely  linked  to  sickle 
vasoocclusion  and  blood  viscosity  were  robustly 
related  to  HbF  concentration  while  complicationsMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Comparative hematological parameters of carrier and non carrier Xmn-1 in HbSS.
                                                                 Mean±SD
Hematological
Parameters
Xmn-1 (+/+)        Xmn-1 (+/-)          Xmn-1 (-/-)
  N=19                      N=27                    N=14
P-value
RBC   millions/μl     3.8±2.3 3.2±1.7 3.5±1.2 0.001
HGB    g/dl             10.3±1.7 9.3±1.5 9.2±1.2 <0.001
HCT     %            20.6±3.4 20.2±1.3 19.8±2.1 <0.001
MCV     fl              73.1±5.2 71.3±4.3 71.5±4.7 <0.001
MCH     pg            31.6±7.4 30.2±3.2 29.6±3.4 <0.001
MCHC    g/dl           32.7±5.2 32.4±3.5 32.6±4.2 <0.001
HbF    % 25.2±4.3 20.18±3.7 13.2±4.5 <0.001
Table 2. Comparative hematological parameters of carrier and non carrier Xmn-1 in HbSβ-thalassemia.
                                                                 Mean±SD
Hematological
Parameters
Xmn-1 (+/+)      Xmn-1 (+/-)            Xmn-1 (-/-)
N=24                       N=30                   N=21
P-value
RBC   millions/μl     3.7±1.2 3.2±1.7 2.8±1.5 <0.001
HGB    g/dl             10.8±1.2 9.3±1.7 9.2±1.4 <0.001
HCT     %            23.7±3.4 23.8±2.6 21.8±2.1 <0.001
MCV     fl              72.8±6.3 70.9±4.8 68.3±6.5 <0.001
MCH     pg            34.6±5.4 32.6±4.6 32.8±3.4 <0.001
MCHC    g/dl           33.5±3.2 30.7±4.2 30.6±3.1 <0.001
HbF    % 36.2±4.7 32.1±5.2 17.6±4.8 <0.001
Table 3. Comparative clinical parameter with carrier and non carrier Xmn1in HbSS patients.
Frequency %
Clinical Xmn-1 (+/+) Xmn-1 (+/-) Xmn-1 (-/-)
Parameters N=19 N=27 N=14
Anemia 7 (36.84%) 17 (62.96%) 10 (71.42%)
Hepatomegaly 3 (15.78%) 6 (22.22%) 4(28.57%)
Splenomegaly 2 (10.52%) 5 (18.51%) 4 (28.57%)
Painful crisis 3 (15.78%) 4 (14.81%) 5 (35.71%)
Gall stone 2 (10.52%) 4 (14.81) 5 (21.42%)
Acute chest syndrome 2 (10.52%) 4 (14.81%) 3 (21.42%)
Jaundice 3 (15.78%) 4 (14.81%) 3 (21.42%)
Hyper pigmentation 4 (21.05%) 2 (7.4%) 2 (14.28%)
Avascular necrosis 3 (15.78 %) 2 (7.4%) 2 (14.28%)
Retinopathy 2 (10.52%) 1 (3.7%) 1 (7.14)
Septicemia 1 (5.26%) 2 (7.4%) None
Deep vein thrombosis None 1 (3.7%) None
Pulmonary embolism 1 (5.26%) None None
Leg ulcer 1 (5.26% ) None 1(7.14%)
Frequency of blood transfusion 7 (36.84 %) 9 (33.33%) 4 (28.57%)
associated  with  the  intensity  of  hemolysis  were  less 
affected. Although HbF is the protective factor for leg 
ulcers, one complication closely associated with hyper-
hemolysis.
17,18   The effect of -158 C > T mutation on 
expression of Gγ globin gene has been the subject of 
considerable interest. The association of some β-globin 
mutations  with  Xmn1  site  with  elevated  HbF 
expression has been previously published. The role of 
increased HbF response as an ameliorating factor has 
become evident in patients who were mildly affected 
despite being homozygotes or compound heterozygotes 
for β
0 or β
+ thalassaemia.
19 Association of Xmn1 and 
frequency  of  blood  transfusion  was  reported  in 
thalassemic patients.
20, 21 
The  strong  association  of  Xmn1  site  with  the  Arab 
Indian haplotype is thought to be associated with high 
fetal  hemoglobin  concentration  and  confer  a  benign 
course  of  the  disease.  However,  the  clinical 
presentation of sickle cell disease in different regions 
in  our  country  is  highly  variable.
22    In  our  cases, 
hematological  parameters  of  sickle  homozygous  and 
sickle β-thalassemia an improved condition with Xmn1 
carriers while non carriers of Xmn1polymorphism were 
found worsened. Our cases of sickle cell patient Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 4. Comparative clinical parameter with carrier and non carrier Xmn1in HbSβ –thalassemia patients.
Frequency %
Clinical Xmn-1 (+/+) Xmn-1 (+/-) Xmn-1 (-/-)
Parameters N=24 N=30 N=21
Anemia 11 (45.83%) 16 (53.33 %) 14 (66.66 %)
Hepatomegaly 3 (15.78%) 8 (26.66 %) 5 (23.8%)
Splenomegaly 6 (25 %) 9 (30%) 7 (33.34%)
Painful crisis 7 (29.16 %) 9 (30 %) 10 (47.61 %)
Gall stone 6 (25 %) 8 (26.66%) 7 (33.33%)
Acute chest syndrome 5 (20.84%) 7 (23.34%) 7 (33.34)
Jaundice 4 (16.67%) 6 (20%) 5 (23.8%)
Hyper pigmentation 2 (8.33%) 3 (10%) 2 (9.52 %)
Avascular necrosis 1 (4.16%) 3 (10 %) 2(9.52 %)
Retinopathy None 2 (6.66 %) 1 (4.76 %)
Septicemia 2 (8.33 %) 1 (3.33 %) None
Deep vein thrombosis 1 (4.16 %) None 1 (4.76%)
Leg ulcer 2 (8.33 %) 1 (3.33 %) 2 (9.52 %)
Frequency of blood transfusion 9 (37.5 %) 13 (43.33%) 10 (47.61 %)
showed the presence of C-T variation at position -158 
in  the  Gγ  gene,  affect  hematologically  as  well  as 
clinically  and  increased  production  of  HbF.  Xmn1 
carriers of HbSβ-thalassemia patients had higher HbF 
than  HbSS  patients.  The  clinical  features  of  HbS-β 
thalassemia  are  extremely  variable,  ranging  from  a 
completely  asymptomatic  state  to  a  severe  disorder 
similar  to  homozygous  sickle  cell  disease.  This 
heterogeneity  is  likely  to  be  due  to  the  presence  of 
different  β-thalassemia  alleles  or  interaction  with 
modulating  genetic  factors  like  associated  α-
thalassemia and/or a gene for raised HbF production 
(Xmn1 polymorphism).
23 Heterozygosity for presence 
of Xmn1 site polymorphism is also likely to influence 
phenotype
24 and  Xmn1  polymorphism  absence 
reduction is associated with acquired HbF elevation.
25  
Gilmans
13data are consistent with the hypothesis that T 
at position - 1 58 causes the high HbF values. There is 
a paucity of data in relation of Xmn1polymorphism and 
phenotypic effect on Indian sickilers. However a study 
on  HbEβ-thalassemia  report  the  phenotypic effect  of 
Xmn1 polymorphism
17 while another study report none 
of the association in clinical severity and presence of 
Xmn1  polymorphism  in  thalassemia  intermedia 
patients.
26 Raina et al.
27 concluded that the presence of 
Xmn1 polymorphism and IVS 1-1 mutation leads to a 
milder phenotypic presentation causing a delay in onset 
of blood transfusions but dose not effect the amount of 
blood  received /kg/year.  However α-thalassemia  also 
influence  on the level of HbF in patients with sickle 
cell disease.
28,29  In our cases the frequency of Xmn1 
polymorphism      found    higher  amongst    sickle  cell 
anemia  patient in comparison to sickle β thalassemia. 
Sickle  homozygous and  sickle β-thalassemia  patients 
showed clinical variation and this could be due to the 
association  of  Xmn1polymorphism,  either  in 
homozygous  or  heterozygous  state.  Presence  of 
Xmn1polymorphism in sickle patients with higher HbF 
that improve phenotypic presentation in the sickle cell 
patients. A study from Western Iran in β- thalassemia 
patients report the presence of Xmn1 polymorphic site 
on both chromosomes (+/+) the level of Hb F tended to 
be increased compared to the absence of Xmn1 (−/−) 
and  the  presence  of  this  polymorphic  site  caused  a 
positive  influence  on  Hb  F  production  and  the 
Gγ 
percent which could improve the clinical symptoms of 
β-thalassemia  patients.
30 Our  finding  in  sickle  cell 
disease patients was similar with the study. Thus we 
conclude  that  the  phenotypes  of  Indian  sickle  cell 
patients  were  greatly  influenced  by 
Xmn1polymorphism.
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